AI Article Synopsis
- * Results show that patients requiring two courses of induction chemotherapy (IND2) to reach CR have poorer prognostic outcomes compared to those achieving CR after one course (IND1), with higher risks of relapse and death.
- * Several adverse factors, such as age and specific genetic markers, influenced outcomes, emphasizing that the initial response to chemotherapy remains significant even after transplant.
Article Abstract
Introduction: For the majority of patients with acute myeloid leukemia (AML) an allogeneic stem cell transplant (SCT) in first complete remission (CR) is preferred. However, whether the number of courses required to achieve CR has a prognostic impact is unclear. It is unknown which factors remain important in patients requiring more than one course of induction to attain remission.
Methods: This Acute Leukaemia Working Party study from the European Society for Blood and Marrow Transplantation identified adults who received an allograft in first CR from either a fully matched sibling or 10/10 or 9/10 human leucocyte antigen (HLA)-matched unrelated donor (HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ). Univariate and multivariate analyses were undertaken to identify the prognostic impact of one or two courses of induction to attain CR.
Results: A total of 4995 patients were included with 3839 (77%) patients attaining a CR following one course of induction chemotherapy (IND1), and 1116 patients requiring two courses (IND2) to attain CR. IND2 as compared to IND1 was a poor prognostic factor in a univariate analysis and remained so in a multivariate Cox model, resulting in an increased hazard ratio of relapse (1.38; 95% confidence interval [CI], 1.16-1.64; p = .0003) and of death (1.27; 95% CI, 1.09-1.47; p = .002). Adverse prognostic factors in a multivariate analysis of the outcomes of patients requiring IND2 included age, FLT3-ITD, adverse cytogenetics, and performance status. Pretransplant measurable residual disease retained a prognostic impact regardless of IND1 or IND2.
Conclusion: Initial response to chemotherapy as determined by number of courses to attain CR, retained prognostic relevance even following SCT in CR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.35308 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perioperative infections as a prognostic risk factor in hepatocellular carcinoma and cholangiocellular carcinoma: a comparative analysis.
World J Surg Oncol
January 2025
Department for General, Visceral and Pediatric Surgery, Medical Faculty, Heinrich Heine University Düsseldorf, University Hospital Düsseldorf, Düsseldorf, Germany.
Background: Hepatocellular Carcinoma (HCC) and cholangiocellular adenocarcinoma (CCA) are the most common primary liver tumors representing a major global health burden. In early disease stages, tumor resection may provide long-term survival in selected patients. However, morbidity and mortality rates are still relatively high after extended liver surgery with perioperative bacterial infections representing major complications.
View Article and Find Full Text PDFPrognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.
BMC Cancer
January 2025
Department of Respiratory Medicine and Oncology, Yokohama Municipal Citizen's Hospital, 1-1, Mitsuzawa Nishimachi, Kanagawa Ku, Yokohama, 221-0855, Japan.
Introduction: The systemic immune-inflammation index (SII) has emerged as a promising prognostic marker in various malignancies. However, its prognostic significance in patients with small-cell lung cancer (SCLC) treated with immune checkpoint inhibitors (ICIs) remains unclear. In this study, we evaluated the prognostic impact of the SII in patients with SCLC after ICI use.
View Article and Find Full Text PDFAn analysis of extraskeletal osteosarcoma based on the literature.
Sci Rep
January 2025
Department of Orthopedics, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, 305 East Zhongshan Road, Nanjing, 210002, Jiangsu, China.
Extraskeletal osteosarcoma (ESOS) is a very rare malignant tumor. This study aimed to provide more evidence about the natural history and clinical features of ESOS, and clarify the impact of chemotherapy (CT) and radiotherapy (RT) on patient survival and postoperative recurrence for the sake of gaining a better understanding about the disease. Patient/tumor characteristics, recurrence, treatment, and follow-up durations were collected by searching studies in PubMed, Web of Science, Ovid, Elsevier, SpringerLink, Chinese National Knowledge Infrastructure (CNKI), and WAN FANG Data before June 30, 2023.
View Article and Find Full Text PDFSubtype-specific prognostic impact of Bcl-2 in HER2-positive and HER2-negative breast cancer.
Sci Rep
January 2025
Department of Surgery, Yonsei University Wonju College of Medicine, Wonju, Korea.
Bcl-2, a key regulator of cellular apoptosis, is typically linked to adverse prognosis in solid tumors due to its inhibition of apoptotic cell death and promotion of cellular proliferation, leading to tumor progression. However, studies on Bcl-2 in breast cancer have shown inconsistent results, with some indicating favorable outcomes. This study aims to determine the subtype-specific role of Bcl-2 in breast cancer.
View Article and Find Full Text PDFSignificance of location and extent of perineural invasion in early-stage oral cavity squamous cell carcinoma.
Histopathology
January 2025
Department of Pathology, Cork University Hospital, Cork.
Aims: Perineural invasion (PNI) is associated with survival in oral cavity squamous cell carcinoma (OCSCC). There is evidence to suggest that PNI location and extent may be of additional significance. The primary aim of this study was to evaluate the prognostic ability of PNI, including location and extent, in early-stage OCSCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!